Roberto A Cruz1,2, Sana Chaudhary3, Myriam Guevara3, Ethan Meltzer4. 1. Department of Neurology, University of Texas Rio Grande Valley School of Medicine, McAllen, TX, USA. 2. DHR Health Neurology Institute, McAllen, TX, USA. 3. Department of Rheumatology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 4. Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, TX, USA. Ethan.Meltzer@austin.utexas.edu.
Abstract
PURPOSE OF REVIEW: To review the pathophysiology, presentation, and treatment of neuromyelitis optica spectrum disorder (NMOSD) and its association with systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). RECENT FINDINGS: NMOSD is an autoimmune disorder of the central nervous system that primarily targets astrocytes. Although the prevalence is unknown, the coexistence of NMOSD and SLE/SS is well-recognized. Patients with both NMOSD and SLE or SS require may require unique approaches to diagnosis and management. Coexistence of NMOSD and SLE/SS is important for the rheumatologist and neurologist to be able to recognize. For the rheumatologist, NMOSD and its neurologic symptoms represent a distinct disease process from neurologic complications of the patient's underlying connective tissue disease, and it requires distinct acute and chronic management. For the neurologist, the coexistence of SLE and SS can help to establish a diagnosis of NMOSD, or in some situations, the development of neurologic symptoms secondary to NMOSD can lead to the diagnosis of connective tissue disease.
PURPOSE OF REVIEW: To review the pathophysiology, presentation, and treatment of neuromyelitis optica spectrum disorder (NMOSD) and its association with systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). RECENT FINDINGS: NMOSD is an autoimmune disorder of the central nervous system that primarily targets astrocytes. Although the prevalence is unknown, the coexistence of NMOSD and SLE/SS is well-recognized. Patients with both NMOSD and SLE or SS require may require unique approaches to diagnosis and management. Coexistence of NMOSD and SLE/SS is important for the rheumatologist and neurologist to be able to recognize. For the rheumatologist, NMOSD and its neurologic symptoms represent a distinct disease process from neurologic complications of the patient's underlying connective tissue disease, and it requires distinct acute and chronic management. For the neurologist, the coexistence of SLE and SS can help to establish a diagnosis of NMOSD, or in some situations, the development of neurologic symptoms secondary to NMOSD can lead to the diagnosis of connective tissue disease.
Authors: Eoin P Flanagan; Philippe Cabre; Brian G Weinshenker; Jennifer St Sauver; Debra J Jacobson; Masoud Majed; Vanda A Lennon; Claudia F Lucchinetti; Andrew McKeon; Marcelo Matiello; Nilifur Kale; Dean M Wingerchuk; Jay Mandrekar; Jessica A Sagen; James P Fryer; Angala Borders Robinson; Sean J Pittock Journal: Ann Neurol Date: 2016-04-04 Impact factor: 10.422
Authors: Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker Journal: Lancet Date: 2004 Dec 11-17 Impact factor: 79.321
Authors: Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann Journal: Brain Date: 2002-07 Impact factor: 13.501
Authors: Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca Journal: Neurology Date: 2019-02-15 Impact factor: 9.910
Authors: Liqun Liu; Li Tang; Lu Zhang; Xingfang Li; Peng Huang; Jie Xiong; Yangyang Xiao; Lingjuan Liu Journal: Front Immunol Date: 2022-05-02 Impact factor: 7.561